Prostate Cancer Biomarker Enrichment and Treatment Selection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Prostate Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This testing will be done on a samples of blood to see whether or not patients are eligible to take part in one of the sub-studies. Each study will be looking at what effects a new drug or drugs has on prostate cancer and will also be looking at the side effects of treatment. The purpose of the main...
This testing will be done on a samples of blood to see whether or not patients are eligible to take part in one of the sub-studies. Each study will be looking at what effects a new drug or drugs has on prostate cancer and will also be looking at the side effects of treatment. The purpose of the main studies is to see if the biomarkers that were identified screening samples can help predict which patients are most likely to be helped by that drug or drugs and to see how the cancer cells respond to treatment.
Tracking Information
- NCT #
- NCT03385655
- Collaborators
- Canadian Cancer Clinical Trials Network
- BC Cancer Foundation
- Investigators
- Study Chair: Michael Kolinsky Cross Cancer Institute, Edmonton, AB Canada Study Chair: Som Mukherjee Juravinski Cancer Centre at Hamilton Health Sciences Centre, ON Canada Study Chair: Michael Ong Ottawa Hospital Research Institute, Ottawa, ON Canada Study Chair: Kim Chi BCCA - Vancouver Cancer Centre Study Chair: Aaron Hansen University Health Network, Toronto, ON, Canada Study Chair: Sebastien Hotte Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON Canada Study Chair: Zineb Hamilou CHUM-Centre Hospitalier de l'Universite de Montreal
Get Well Soon